Group 1 - The company N北芯-U (688712) was listed today, opening with a significant increase of 187.16%, and closing the morning session with a rise of 185.67% [1][2] - The total trading volume for the half-day reached 21.47 million shares, with a transaction value of 1.082 billion yuan, resulting in a turnover rate of 57.85% [1][2] - The company specializes in the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, positioning itself as a national high-tech enterprise [1] Group 2 - The core products include the intravascular ultrasound (IVUS) diagnostic system, which is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, and the fractional flow reserve (FFR) measurement system, which is the first domestic product in the FFR field approved by the same authority [1] - Both products have entered the special review process for innovative medical devices, potentially transforming clinical practices for percutaneous coronary intervention (PCI) surgeries [1] - The company is the first domestic medical device company to offer a combination of vascular functional FFR and imaging IVUS products, filling a gap in the domestic market and changing the reliance on imported products for precise diagnosis of coronary artery diseases in China [1]

Core Insights - The article highlights the significant growth in the approval of innovative medical devices in China, indicating a strong focus on innovation and regulatory support in the sector [1] Group 1: Approval Statistics - In 2025, a total of 76 innovative medical devices were approved for market entry, representing a year-on-year increase of 17%, with a cumulative total of 391 devices approved [1] - There were 25 medical devices that received priority approval for market entry, showing a remarkable year-on-year growth of 212.5%, leading to a cumulative total of 171 devices approved [1]

Core Viewpoint - North Chip Life officially listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on February 5, 2026, with an issue price of 17.52 yuan per share, marking it as the third company to successfully list under the fifth set of standards and the first domestic medical device company in this category [2] Company Positioning - North Chip Life, established in December 2015 and headquartered in Shenzhen, focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [4] - It is the first domestic medical device company to possess a combination of intravascular functional FFR and imaging IVUS products, breaking the reliance on imported products for clinical precision diagnosis of coronary artery diseases in China [4] Product Overview - The company has accumulated over 20 Class III medical device registrations, with core products including China's first approved domestic 60MHz high-definition IVUS system and the first approved domestic gold standard FFR system, enhancing accessibility to cardiovascular precision diagnosis in China [5][6] - As of the signing date of the prospectus, North Chip Life has 17 approved and in-development cardiovascular interventional medical device products, covering five categories: IVUS diagnostic systems, FFR measurement systems, vascular access products, shockwave balloon treatment systems, and electrophysiological solutions [6] Technological Advancements - In 2025, the company plans to launch the first domestic integrated solution for coronary function and the first domestic peripheral IVUS catheter, achieving a key breakthrough in the electrophysiology field with the "single-shot" technique for pulsed electric field ablation [7] - The TRUEVISION® & VivoHeart® intravascular ultrasound diagnostic system is the first domestically developed IVUS product, featuring industry-leading imaging resolution (60MHz) and speed (100 frames per second) [8] Market Implications - In the context of cardiovascular intervention, IVUS and FFR are not merely auxiliary tools but are core infrastructures that directly influence lesion assessment, surgical strategy, and efficacy evaluation [18] - The long-term value of North Chip Life is not solely dependent on whether a single product can replace imports but on its ability to continuously integrate domestic precision diagnostic tools into real clinical workflows, establishing a verifiable and replicable business model [18]

Core Viewpoint - Boston Scientific's recent quarterly earnings report showed strong revenue and profit growth, but the stock price declined due to concerns over the slower-than-expected growth in the electrophysiology segment, which is critical for investor sentiment [1][5][6]. Overall Performance: Revenue and Profit Exceed Expectations - For Q4 2025, net sales reached $5.286 billion, a year-on-year increase of 15.9% (reported basis) and 12.7% organic growth [2][4]. - Net profit was $672 million, reflecting an 18.7% year-on-year growth, with adjusted earnings per share at $0.80, slightly above market expectations [2][3]. Stock Price Decline: Issues in Key Segment - Despite exceeding overall earnings expectations, Boston Scientific's stock price fell by over 10% in pre-market trading and nearly 15% during the day, primarily due to concerns in the electrophysiology (EP) segment [5]. - The EP segment's growth was approximately 35% year-on-year but fell short of market expectations by about 5 percentage points, leading to a revenue shortfall of approximately $33 million compared to consensus estimates [6][18]. Importance of Electrophysiology Segment - The electrophysiology segment, while not the largest, is one of the most scrutinized by capital markets due to its perceived strategic importance [6]. - The competitive landscape for pulsed field ablation (PFA) technology is intensifying, with Boston Scientific facing pressure on its market share as competitors enter the space [7][18]. Overall Business Growth - Excluding the electrophysiology segment, Boston Scientific's overall business remains robust, with significant growth across various segments [8][9]. - Key segment performances for Q4 included: - Cardiovascular: 18.2% growth - Urology: 13.8% growth - MedSurg: 11.7% growth - Neuromodulation: 11.1% growth - Endoscopy: 10.1% growth [12]. Mergers and Products: Strengthening Multi-Track Layout - In Q4 2025, Boston Scientific continued to pursue mergers and product advancements to diversify its portfolio, indicating a proactive approach to reduce reliance on any single product line [11][13]. - The company completed the acquisition of Nalu Medical and secured multiple agreements related to neurovascular technologies, enhancing its competitive positioning [13]. 2026 Guidance: Continued High Growth - Boston Scientific maintains a strong outlook for 2026, projecting double-digit revenue growth despite already exceeding $20 billion in size, which is uncommon among global medical device giants [15]. Conclusion: Market Reassessing Growth Structure - The key takeaway from the earnings report is not a slowdown in growth but rather a market reassessment of growth structures, emphasizing the importance of multi-segment collaboration over reliance on a single standout product [16][18].

Core Insights - Nina Goodheart, the Senior Vice President and President of Medtronic's Structural Heart and Aortic business, announced her retirement after nearly 20 years with the company, marking the end of a significant career [1][3] Group 1: Leadership Background - Nina Goodheart joined Medtronic in 2007, initially focusing on the Cardiac Rhythm and Heart Failure (CRDM) market, and later held various key management positions [3] - Over the past five years, she led the Structural Heart and Aortic business, witnessing its evolution from a single product competition to a platform-based approach with expanded indications and long-term follow-up [3][5] Group 2: Business Progress During Tenure - Under her leadership, the core focus of Medtronic's Structural Heart business was clear, emphasizing the following: 1. Continuous advancement of the transcatheter aortic valve platform 2. Differentiated layout for transcatheter pulmonary valves 3. Promotion of clinical research and conceptual development [6] - The Evolut series of transcatheter aortic valve systems has seen ongoing iterations, maintaining a leading position in the global TAVR competition, while the Harmony transcatheter pulmonary valve system targets a niche market with high technical barriers [7] Group 3: Conclusion and Industry Implications - Goodheart's retirement is viewed as a normal conclusion of an executive career cycle rather than a sign of business pressure or strategic shifts [9] - The news holds value for industry stakeholders interested in how global leaders in the mature structural heart business achieve long-term stable operations [9]

今年科创板首个医疗IPO诞生了。 今日（2月5日），深圳北芯生命科技股份有限公司（简称"北芯生命"）正式在科创板上市。本次IPO发行价为17.52元/ 股，开盘后大涨超200%，市值超200亿元。 公司掌舵人是80后博士宋亮。早年毕业于武汉大学，后弃理从医赴美留学。回国后，他敏锐识别出心血管精准诊疗领 域的关键技术空白，毅然辞职创业。十年历程，北芯生命身后集结了一支长长的投资人队伍，颇为壮观。 自科创板第五套上市标准重启后，北芯生命成为首家成功登陆的医疗器械企业，也是2024年以来首家在科创板敲钟的 国产高端医疗器械公司。今天这声钟响不只属于北芯生命，也像是在提醒市场："医疗IPO的节奏回来了"。 始于深圳，200亿，武大校友敲钟 宋亮，1982年出生于湖南，17岁时考入武汉大学。原本他计划专注于物理学，但一次偶然的机会接触到了生命科学。 后来赴美深造，并在华盛顿大学获得生物医学工程博士学位。 2011年，宋亮回国后来到深圳，加入中国科学院深圳先进技术研究院。在院方支持下，短短两三年的时间，他从零开 始组建了生物医学光学与分子影像研究室。 转折发生在与医院的深度合作中。宋亮开始"倒着思考"：临床医生是如何想的 ...

来源：新浪证券-红岸工作室 2月4日，春立医疗跌1.24%，成交额4912.14万元。两融数据显示，当日春立医疗获融资买入额685.33万 元，融资偿还334.07万元，融资净买入351.26万元。截至2月4日，春立医疗融资融券余额合计5033.11万 元。 融资方面，春立医疗当日融资买入685.33万元。当前融资余额5032.65万元，占流通市值的0.76%，融资 余额超过近一年90%分位水平，处于高位。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167.00万股。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina ...

摘 要 ： 中 国 海 关 科 学 技 术 研 究 中 心 牵 头 制 定 的 国 家 标 准 《 快 速 核 酸 检 测 仪 性 能 的 测 定 方 法 》 （GB/T47026-2026）正式发布，填补了我国核酸快检设备性能评价国家标准空白，标志着标准化建设 迈出重要一步。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近日，中国海关科学技术研究中心（以下简称海科中心）牵头制定的国家标准《快速核酸检测 仪性能的测定方法》（GB/T 47026-2026）正式发布。该标准系依托海科中心仪器设备验 证与综合评价认证平台，联合该验评平台成员单位、科研院所及国内优秀仪器设备生产企业等 多方技术力量共同起草，为我国首项关于核酸快检设备的性能评价国家标准，成功填补了该领 域空白，标志着我国相关领域标准化建设迈出重要一步。 长期以来， 快速核酸检测仪性能评价缺乏统一的国家级标准 ，给仪器研发、生产质控、用户 选型及行业监管带来诸多不便。该标准系统描述了快速核酸检测仪关键性能指标的测定方法， 为相关工作提供了权威、统一的科学依据。标准制定过程充分体 ...

Core Insights - North Chip Life Technology Co., Ltd. has officially listed on the STAR Market, marking the first medical IPO of the year and achieving a market capitalization exceeding 20 billion yuan shortly after its debut [1][2] - The company was founded by Dr. Song Liang, who identified a critical technology gap in cardiovascular precision diagnosis and has since developed innovative medical devices [1][3] - North Chip Life is the first domestic high-end medical device company to successfully list on the STAR Market since the resumption of the fifth set of listing standards [1][5] Company Background - Dr. Song Liang, born in 1982, graduated from Wuhan University and later obtained a Ph.D. in biomedical engineering from the University of Washington [2] - After returning to China, he established a research lab at the Shenzhen Institute of Advanced Technology and began focusing on clinical needs in cardiovascular disease treatment [2][3] - The company was founded in 2015 and has developed the first domestic FFR system based on MEMS sensors, addressing a significant market gap [3] Product Development - North Chip Life has developed a total of 17 products in the cardiovascular interventional medical device field, including FFR systems and IVUS systems, with clinical applications in over 1,000 hospitals globally [3][4] - The company achieved a market-leading position with its 60MHz high-definition IVUS product shortly after its approval in China [3] Financial Performance - The company reported revenues of 92.45 million yuan in 2022, with projections of 184 million yuan and 317 million yuan for 2023 and 2024, respectively [4] - North Chip Life turned a profit before its IPO, with a net profit of 49.44 million yuan in the first half of 2025, indicating growing recognition in the global market [4] Investment and Support - The company has attracted significant investment from notable venture capital and private equity firms, including Sequoia China and Qiming Venture Partners, reflecting strong confidence in its growth potential [6][9] - North Chip Life has successfully completed multiple funding rounds, with key investors supporting its strategic vision and product development [8][9] Market Context - The IPO of North Chip Life signals a reopening of the A-share market for medical companies, with several other firms also preparing for listings [11][13] - The recent trend indicates a growing interest in domestic medical innovations, with many companies seeking to capitalize on favorable market conditions [12][14]

拉开序幕。 作者/王露 报道/投资界PEdaily 今年科创板首个医疗I PO诞生了。 今日（2月5日），深圳北芯生命科技股份有限公司（简称"北芯生命"）正式在科创板上市。本次I PO 发行价为1 7 . 5 2元/股， 开盘后大涨超2 0 0 %， 市值超2 0 0亿元。 公司掌舵人是8 0后博士宋亮。早年毕业于武汉大学，后弃理从医赴美留学。回国后，他敏锐识别出心 血管精准诊疗领域的关键技术空白，毅然辞职创业。十年历程，北芯生命身后集结了一支长长的投资 人队伍，颇为壮观。 自科创板第五套上市标准重启后，北芯生命成为首家成功登陆的医疗器械企业，也是2 0 2 4年以来首家 在科创板敲钟的国产高端医疗器械公司。今天这声钟响不只属于北芯生命，也像是在提醒市场： "医 疗IPO的节奏回来了"。 始于深圳 200亿，武大校友敲钟 宋亮，1 9 8 2年出生于湖南，1 7岁时考入武汉大学。原本他计划专注于物理学，但一次偶然的机会接触 到了生命科学。后来赴美深造，并在华盛顿大学获得生物医学工程博士学位。 2 0 11年，宋亮回国后来到深圳， 加入中国科学院深圳先进技术研究院。 在院方支持下，短短两三年 的时间，他从零开始 ...